Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Nov 28, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Nov 28, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 6-k, disclosure
TL;DR
Innate Pharma dropped a 6-K on 11/28/25, likely a press release update. No big news yet.
AI Summary
Innate Pharma SA filed a Form 6-K on November 28, 2025, reporting a press release dated November 28, 2025. The filing does not contain specific financial figures or operational details beyond the report date and company information.
Why It Matters
This filing indicates a routine disclosure from Innate Pharma SA, a foreign private issuer, to the SEC. It serves as an update mechanism for investors regarding company announcements.
Risk Assessment
Risk Level: low — The filing is a standard Form 6-K, which typically contains routine disclosures and press releases, not significant new financial or strategic information that would immediately impact risk.
Key Players & Entities
- Innate Pharma SA (company) — Registrant
- November 28, 2025 (date) — Report Date
- 117 Avenue de Luminy—BP 30191 13009 Marseille, France (address) — Principal Executive Office
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that is furnished to the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country or that it furnishes or is required to furnish to its security holders.
What specific information is included in this Innate Pharma 6-K filing?
This filing includes a press release dated November 28, 2025, as Exhibit 99.1, and provides basic company information such as its address and SEC file number.
When was this Form 6-K filed with the SEC?
The Form 6-K was filed on November 28, 2025.
Is Innate Pharma SA required to file annual reports on Form 20-F or 40-F?
Yes, Innate Pharma SA indicates it files annual reports under cover of Form 20-F.
What is Innate Pharma SA's primary business according to the filing?
Innate Pharma SA is classified under the Standard Industrial Classification code 2836 for Biological Products (No Diagnostic Substances).
Filing Stats: 159 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-11-28 09:07:51
Filing Documents
- a6k-iphx251128.htm (6-K) — 8KB
- exhibit991-251128.htm (EX-99.1) — 17KB
- 0001628280-25-054231.txt ( ) — 27KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date November 28, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive Officer